About me
Brian Doyle has over 15 years of experience in technical and CMC development for vaccines and therapeutics. Since joining Moderna in 2019, Brian has led organizations focused on late-stage and commercial process development and CMC technical writing, with a particular interest at the interface between process and regulatory science related to platform-based approaches. Prior to joining Moderna, Brian held roles in roles in cell culture and fermentation process development at Gilead Sciences and Merck. Brian holds a B.S. in Chemical-Biological Engineering from the Massachusetts Institute of Technology.
